Lactobacillus Plantarum and Hormonal Regulation in Obese Women
Launched by WECARE PROBIOTICS CO., LTD. · May 15, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a specific probiotic called Lactobacillus plantarum Lp90 might help manage fat in the body and balance hormones in women who are obese. The researchers want to see if this probiotic can make a difference in how the body processes fat and regulates hormones, which could be important for overall health.
To participate, women need to be between 18 and 40 years old and have a body mass index (BMI) of 25 or higher, indicating obesity. Participants will be asked to take the probiotic every day and provide some blood, urine, and stool samples during the study. It's important that they can hear and understand instructions clearly. However, women with certain health conditions, such as serious digestive or neurological disorders, or those currently receiving treatment for mental health issues, will not be eligible. If you're interested in joining, you'll be contributing to valuable research that could help improve health for many women in the future.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Age: 18 to 40 years old, female, BMI ≥ 25 kg/m2.
- • 2. Be willing to receive follow-up during the intervention period.
- • 3. Be willing to provide two blood, urine and fecal samples during the intervention period.
- • 4. Be willing to take the compound probiotics by oneself every day during the intervention period.
- • 5. Have good hearing and be able to hear and understand all instructions during the intervention period.
- • -
- Exclusion Criteria:
- • 1. Suffering from digestive system diseases, mainly gastrointestinal diseases (celiac disease, ulcerative colitis, Crohn's disease).
- • 2. Suffering from severe neurological disorders (epilepsy, stroke, severe head trauma, meningitis within the past 10 years, brain surgery, brain tumor, long-term coma - excluding general anesthesia).
- • 3. Have received/are currently receiving treatment for the following mental illnesses: alcohol/drug/substance abuse dependence, schizophrenia, psychosis, bipolar disorder.
- • 4. Take medication for depression or low mood.
- • 5. Suffering from internal organ failure (such as heart, liver or kidney failure, etc.).
- • 6. Have received radiotherapy or chemotherapy in the past.
- • 7. Have received general anesthesia surgery/procedures within the past three years, or plan to receive general anesthesia procedures/surgeries within the next three months during this trial.
- • 8. Have suffered from hepatitis (hepatitis B, hepatitis C), HIV or syphilis in the past.
- • -
About Wecare Probiotics Co., Ltd.
wecare probiotics co., ltd. is a leading biotechnology firm dedicated to advancing gut health through innovative probiotic solutions. With a robust portfolio of research and development initiatives, the company focuses on formulating high-quality probiotic products that are backed by scientific evidence. Committed to enhancing the well-being of individuals, wecare probiotics collaborates with healthcare professionals and academic institutions to conduct clinical trials that evaluate the efficacy and safety of its formulations. The company's mission is to empower consumers with effective, research-driven probiotic options, fostering a healthier future for all.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zhengzhou, Henan, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported